ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2010
[Expression and clinical significance of SHP2 in the tumor tissues of smokers with lung cancer].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Role of SHP2/PTPN11 in the occurrence and prognosis of cancer: A systematic review and meta-analysis.Oncology letters · 2023Article
- Article
- Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveIt has been proved that protein phosphorylation and dephosphorylation were important mechanisms in lung cancer development, and tobacco smoking is an important risk factor of lung cancer. The aim of this study is to investigate the expression and clinical significance of protein tyrosine phosphatase SHP2 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC); the relationship between tobacco smoking and the expression of SHP2 is also studied.
methodsImmunohistochemistry (Invision) and fluorescence in situ hybridization (FISH) were used to detect the expression of SHP2 and the augment of SHP2 mRNA in the 53 lung cancer specimens.
resultsThe weak positive rate of SHP2 was 80% (which was also the total positive rate) in normal bronchial epithelium. The weak, moderate and strong positive rates were 35.4%, 43.8% and 6.2% (total positive rate was 85.4%) in 48 NSCLC patients, 0%, 80% and 20% (total positive rate was 100%) in 5 SCLC patients, 40.7%, 37.4% and 3.7% (total positive rate was 81.5%) in the tumor tissues of 27 NSCLC patients who didn't smoke and 23.8%, 71.4% and 4.7% (total positive rate was 100%) in the tumor tissues of 21 NSCLC patients whose smoking indexes were ≥ 400. Significant differences of SHP2 expression were observed between tumor tissues and normal bronchial epithelium, NSCLC and SCLC, and between different smoking indexes (P<0.05).
conclusionsThe enhancement of SHP2 expression in the tumor tissues of NSCLC patients who smoke may be correlated with tobacco smoking; SHP2 may play certain role in the development of lung cancer; SHP2 prospectively provides new ideas for the drug research and development of lung cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.